Pharmafile Logo
Pharmafocus logo
Advanced Search

central nervous system

Showing 7 posts of 7 posts found.

Julius Clinical appoints Bassem Saleh as CEO

October 16, 2025
Julius Clinical, cardiometabolic diseases, central nervous system

Julius Clinical, a Netherlands-based clinical research organisation (CRO), has appointed Bassem Saleh as its new chief executive officer (CEO). Saleh …

Appointment

Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate

July 28, 2025
Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis

Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …

Appointment

MetP Pharma releases positive data on intranasal semaglutide administration

July 22, 2025
Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide

MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …

News
nerve-cell-2213009_960_720

Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders

July 14, 2025
Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions

Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain …

News
angelini_pharma

Angelini Pharma to acquire Arvelle Therapeutics in $960 million deal

January 6, 2021
Research and Development Angelini Pharma, central nervous system

Angelini Pharma is set to acquire Arvelle Therapeutics, a biopharmaceutical company focused on bringing innovative treatments to patients suffering from …

News

US biotech company to try resurrect the clinically dead

May 4, 2016
Research and Development US, bioquark, biotech, brain, central nervous system, clinically dead, dead, patients, ressurect

A US biotech firm has announced plans for a Phase I trial that will see them attempt to bring brain-dead …

News
Teva image

Teva buys majority stake in genomic analysis firm

August 4, 2015
Manufacturing and Production, Research and Development, Sales and Marketing CNS, Immuneering, Teva, central nervous system, genetic analysis

Teva has agreed to by a 51% equity share of genomic-analysis company Immuneering to advance treatments for diseases of the …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026